Abstract
The sulfonamides constitute an important class of drugs, with several types of pharmacological agents possessing antibacterial, anti-carbonic anhydrase, diuretic, hypoglycemic and antithyroid activity among others. A host of structurally novel sulfonamide derivatives have recently been reported to show substantial antitumor activity in vitro and / or in vivo. Although they have a common chemical motif of aromatic / heterocyclic sulfonamide, there are a variety of mechanisms of their antitumor action, such as carbonic anhydrase inhibition, cell cycle arrest in the G1 phase, disruption of microtubule assembly, functional suppression of the transcriptional activator NF-Y, and angiogenesis (matrix metalloproteinase, MMP) inhibition among others. Some of these compounds selected via elaborate preclinical screenings or obtained based on computer-aided drug design, are currently being evaluated in clinical trials. This review summarizes recent classes of sulfonamides and related sulfonyl derivatives disclosed ultimately as effective tumor cell growth inhibitors, or for the treatment of different types of cancer.
Keywords: Sulfonamides, Sulfonylated Derivatives, Anticancer Agents, anti-carbonic anhydrase, diuretic, hypoglycemic, antithyroid, transcriptional activator NF-Y, angiogenesis, matrix metalloproteinase MMP
Current Cancer Drug Targets
Title: Sulfonamides and Sulfonylated Derivatives as Anticancer Agents
Volume: 2 Issue: 1
Author(s): Angela casini, Andrea Scozzafava, Antonio Mastrolorenzo and Claudiu T. Supuran
Affiliation:
Keywords: Sulfonamides, Sulfonylated Derivatives, Anticancer Agents, anti-carbonic anhydrase, diuretic, hypoglycemic, antithyroid, transcriptional activator NF-Y, angiogenesis, matrix metalloproteinase MMP
Abstract: The sulfonamides constitute an important class of drugs, with several types of pharmacological agents possessing antibacterial, anti-carbonic anhydrase, diuretic, hypoglycemic and antithyroid activity among others. A host of structurally novel sulfonamide derivatives have recently been reported to show substantial antitumor activity in vitro and / or in vivo. Although they have a common chemical motif of aromatic / heterocyclic sulfonamide, there are a variety of mechanisms of their antitumor action, such as carbonic anhydrase inhibition, cell cycle arrest in the G1 phase, disruption of microtubule assembly, functional suppression of the transcriptional activator NF-Y, and angiogenesis (matrix metalloproteinase, MMP) inhibition among others. Some of these compounds selected via elaborate preclinical screenings or obtained based on computer-aided drug design, are currently being evaluated in clinical trials. This review summarizes recent classes of sulfonamides and related sulfonyl derivatives disclosed ultimately as effective tumor cell growth inhibitors, or for the treatment of different types of cancer.
Export Options
About this article
Cite this article as:
casini Angela, Scozzafava Andrea, Mastrolorenzo Antonio and Supuran T. Claudiu, Sulfonamides and Sulfonylated Derivatives as Anticancer Agents, Current Cancer Drug Targets 2002; 2 (1) . https://dx.doi.org/10.2174/1568009023334060
DOI https://dx.doi.org/10.2174/1568009023334060 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Regional Differences in Adaptation of CNS Mu Opioid Receptors to Chronic Opioid Agonist Administration
Current Neuropharmacology Clozapine Safety, 40 Years Later
Current Drug Safety Editorial [Hot topic: Controversies in Hypertension Treatment (Guest Editors: Maciej Banach, Sverre E. Kjeldsen and Krzysztof Narkiewicz)]
Current Vascular Pharmacology Thrombomodulin Links Coagulation to Inflammation and Immunity
Current Drug Targets Steroid Biosynthesis Inhibitors in the Therapy of Hypercortisolism: Theory and Practice
Current Medicinal Chemistry Patent Selections:
Recent Patents on Medical Imaging G Protein-Coupled Receptor Kinase 2 - a Feedback Regulator of Gq Pathway Signalling
Current Drug Targets - Immune, Endocrine & Metabolic Disorders EDITORIAL [Hot Topic: Biomarkers in Cardiovascular Disease (Guest Editor: Dimitris Tousoulis)]
Current Medicinal Chemistry Therapeutic Strategies Targeting Endothelial Function in Humans:Clinical Implications
Current Vascular Pharmacology High Glucose-Mediated Imbalance of Nitric Oxide Synthase and Dimethylarginine Dimethylaminohydrolase Expression in Endothelial Cells
Current Neurovascular Research Telephone Follow-up of Older People After Hospital Admissions
Current Aging Science Molecular Mechanisms Involved in the Aging of the T-cell Immune Response
Current Genomics Pre-Emptive Conditioning of the Ischemic Heart
Cardiovascular & Hematological Agents in Medicinal Chemistry Voltage-Gated Sodium Channels: Mutations, Channelopathies and Targets
Current Medicinal Chemistry Reducing the Risk of Major Elective Non-cardiac Surgery: Is there a Role for Levosimendan in the Preoperative Optimization of Cardiac Function?
Current Drug Targets Estrogen Receptor Beta in Cancer: an Attractive Target for Therapy
Current Pharmaceutical Design The Role of Mitochondria in Brain Aging and the Effects of Melatonin
Current Neuropharmacology Can Diet and Physical Activity Limit Alzheimer's Disease Risk?
Current Alzheimer Research Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in the Treatment of Hypertension: Should they be Used Together?
Current Vascular Pharmacology Diastolic Heart Failure and LV Dyssynchrony
Current Pharmaceutical Biotechnology